Canada Gazette, Part I, Volume 160, Number 47: GOVERNMENT NOTICES
November 21, 2026
BANK OF CANADA
PAYMENT CLEARING AND SETTLEMENT ACT
Notice of designation to the Canadian Payments Association
Under subsection 4(1) of the Payment Clearing and Settlement Act (the “Act”), if the Governor of the Bank of Canada is of the opinion that a clearing and settlement system could be operated in a manner that poses a systemic risk or payments system risk, and the Minister of Finance is of the opinion that it is in the public interest to do so, the Governor may designate the system as a clearing and settlement system that is subject to Part I of the Act.
The Real-Time Rail (RTR) is eligible to be designated under the Act, as the RTR has at least three participants, including at least one Canadian participant and at least one participant whose head office is located outside Ontario, where the head office of the Canadian Payments Association (Payments Canada) is located; clearing and settlement are conducted in Canadian dollars; and payment obligations that arise from the system are ultimately settled through adjustments to participants’ accounts at the Bank of Canada.
Payments Canada operates the RTR, which will provide continuous clearing and settlement of payments with immediate availability of funds. The RTR will serve as the clearing and settlement system for Interac e-Transfer, a prominent payment system. Given the role of the RTR in supporting widely used payment services, a disruption to or failure of the RTR could impair the ability of individuals and businesses to make payments and could adversely affect confidence in the Canadian payments system.
I am of the opinion that the RTR could be operated in such a manner as to pose a payments system risk and, therefore, should be designated as subject to Part I of the Act. The Minister of Finance is of the opinion that it would be in the public interest to designate the RTR.
Accordingly, the RTR is hereby designated pursuant to subsection 4(1) of the Act, effective November 8, 2026.
November 8, 2026
Tiff Macklem
Governor
DEPARTMENT OF FINANCE
CONSUMER-DRIVEN BANKING ACT
Financial Data Exchange Inc. — Designation of the technical standards body
Whereas, before designating the technical standards body referred to in subsection 125(1) of the Consumer-Driven Banking Act, the Minister of Finance took into account the factors set out in paragraphs 125(2)(a) to (e) of that Act;
And whereas the Minister of Finance, under paragraph 125(2)(f) of that Act, considered it relevant to also take into account
- (a) the willingness and ability of the body to serve as the designated technical standards body,
- (b) the need for the technical standard to support interoperability between Canada’s consumer-driven banking framework and comparable frameworks in foreign states,
- (c) the ability of the body to ensure that the technical standard is consistent and is not withdrawn, including in the event of the body’s dissolution, and
- (d) the ability of the body to support Canadian-led decision-making;
Therefore, the Minister of Finance, under subsection 125(1) of the Consumer-Driven Banking Act, designates Financial Data Exchange Inc. acting through its FDX Canada Council, to be the technical standards body that is responsible for establishing the technical standard that is to be used for the sharing of data by participating entities in accordance with that Act.
Ottawa, November 13, 2026
François-Philippe Champagne
Minister of Finance
DEPARTMENT OF FINANCE
CONSUMER-DRIVEN BANKING ACT
Ombudsman for Banking Services and Investments — Designation of the external complaints body
Whereas, before designating a corporation to be the external complaints body referred to in subsection 114(1) of the Consumer-Driven Banking Act, the Minister of Finance took into account all factors that the Minister considers relevant, including those set out in subsection 114(2) of that Act;
Therefore, the Minister of Finance, on the recommendation of the Bank of Canada, under subsection 114(1) of the Consumer-Driven Banking Act, designates the Ombudsman for Banking Services and Investments, a corporation incorporated under the Canada Not-for-profit Corporations Act, to be the external complaints body referred to in subsection 114(1) of the Consumer-Driven Banking Act.
Ottawa, November 13, 2026
François-Philippe Champagne
Minister of Finance
DEPARTMENT OF HEALTH
DEPARTMENT OF HEALTH ACT
Notice of annual increase of Health Canada’s Drug Master Files and Certificate of Pharmaceutical Product fees
Notice is hereby given that the Minister of Health, under the Ministerial Authority to Enter into Contract, updates the fees that are payable for the provision of Drug Master Files and Certificate of Pharmaceutical Product services by 2%, rounded up to the nearest dollar.
The current fees and the fees updated as of April 1, 2027, are listed below.
Any inquiries or comments about the updated fees can be directed to Rosslynn Miller-Lee, Director General, Business Facilitation and Modernization Directorate, Health Products and Food Branch, 613‑327‑0798 (telephone) or cro-brc@hc-sc.gc.ca (email).
| Services | Fee as of April 1, 2026 | Fee as of April 1, 2027 |
|---|---|---|
| Certificate of Pharmaceutical Product (or a supplemental copy of a Certificate of Pharmaceutical Product) | $105 | $108 |
| New Master Files (file registration) | $1,436 | $1,465 |
| Drug Master Files — letter of access | $204 | $209 |
| Drug Master Files — update | $624 | $637 |
DEPARTMENT OF HEALTH
FINANCIAL ADMINISTRATION ACT
Notice of annual adjustment of fees for dealer’s licences
Notice is hereby given, under section 19.2 of the Financial Administration Act, that in keeping with section 4 of the Fees in Respect of Dealer’s Licences Regulations, the fee for dealer’s licences: human drugs will increase by the annual 2% amount, rounded up to the nearest dollar. Under subsection 17(1) of the Service Fees Act (a fee is adjusted in each fiscal year — on the anniversary of a date that is selected by the responsible authority with respect to the fee before the first adjustment — by the percentage change over 12 months in the April All-items Consumer Price Index [CPI] for Canada, as published by Statistics Canada under the Statistics Act, for the previous fiscal year), the dealer’s licence: veterinary drugs (as per the Licensed Dealers for Controlled Drugs and Narcotics (Veterinary Use) Fees Regulations) will be adjusted by the CPI. Health Canada has chosen April 1 as the anniversary date. The CPI for this year is 2.8%.
The current fees and the fees updated as of April 1, 2027, are listed below.
Any inquiries or comments about the updated fees can be directed to Rosslynn Miller-Lee, Director General, Business Facilitation and Modernization Directorate, Health Products and Food Branch, 613‑327‑0798 (telephone) or cro-brc@hc-sc.gc.ca (email).
| Type of licence | Fee as of April 1, 2026 | Fee as of April 1, 2027 |
|---|---|---|
| Dealer’s licence (human drugs) | $6,078 | $6,200 |
| Dealer’s licence (veterinary drugs) | $2,192.31 | $2,253.69 |
| Dealer’s licence (veterinary drugs, first year) | $1,096.16 | $1,126.85 |
DEPARTMENT OF HEALTH
FOOD AND DRUGS ACT
Notice of annual adjustment of the Fees in Respect of Drugs and Medical Devices Order
Notice is hereby given, under subsection 30.61(1) of the Food and Drugs Act, that in keeping with section 4.1 of the 2020 Fees in Respect of Drugs and Medical Devices Order, every fee outlined in the Order is to be adjusted annually based on the Consumer Price Index (CPI), rounded up to the nearest dollar. The CPI is calculated based on the percentage change over 12 months in the April All-items CPI for Canada, as published by Statistics Canada under the Statistics Act, for the previous fiscal year. The CPI for this year is 2.8%.
The current fees and the fees updated as of April 1, 2027, are listed below.
Any inquiries or comments about the updated fees can be directed to Rosslynn Miller-Lee, Director General, Business Facilitation and Modernization Directorate, Health Products and Food Branch, 613‑327‑0798 (telephone) or cro-brc@hc-sc.gc.ca (email).
Human Drug Submission Review
Part 2 — Drugs
| Section in the Fees in Respect of Drugs and Medical Devices Order | Submission class | Fee as of April 1, 2026 | Fee as of April 1, 2027 |
|---|---|---|---|
| Section 9 | New active substance | $616,593 | $633,858 |
| Clinical or non-clinical data and chemistry and manufacturing data | $319,282 | $328,222 | |
| Clinical or non-clinical data only | $127,668 | $131,243 | |
| Comparative studies | $71,953 | $73,968 | |
| Chemistry and manufacturing data only | $44,269 | $45,509 | |
| Clinical or non-clinical data only, in support of safety updates to the labelling | $23,368 | $24,023 | |
| Labelling only | $6,436 | $6,617 | |
| Labelling only (generic drugs) | $2,419 | $2,487 | |
| Administrative submission | $1,020 | $1,049 | |
| Disinfectant — full review | $13,411 | $13,787 | |
| Labelling only (disinfectants) | $3,015 | $3,100 | |
| Drug identification number application — labelling standard | $1,945 | $2,000 |
| Section in the Fees in Respect of Drugs and Medical Devices Order | Type of submission | Component | Fee as of April 1, 2026 | Fee as of April 1, 2027 |
|---|---|---|---|---|
| Section 21 | Application for drug identification number (DIN) | Information, other than that referred to in the item below, to support an application for a drug identification number, including the submission of labelling material for a second review, if required | $2,946 | $3,029 |
| Published references or other data | $2,047 | $2,105 | ||
| Documentation to support a change of manufacturer, a change to the name of a manufacturer or a change to the brand name of a drug | $1,025 | $1,054 | ||
| Notification — veterinary health product | Information contained in a notification filed under subsection C.01.615(1) of the Food and Drug Regulations in respect of a veterinary health product | $588 | $605 | |
| New drug submissions (NDS) | Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in one animal species (in the case of an antiparasitic drug, several indications in one food animal species) | $65,297 | $67,126 | |
| Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one non-food animal species |
$39,557 | $40,665 | ||
| Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration and dosage form and two indications in one animal species | $94,961 | $97,620 | ||
| Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species | $128,589 | $132,190 | ||
| Comparative (pharmacodynamic, clinical or bioavailability) data to support an additional route of administration | $11,855 | $12,187 | ||
| Comparative (pharmacodynamic, clinical or bioavailability) data to support each additional strength | $1,964 | $2,019 | ||
| For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1 000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species | $89,035 | $91,528 | ||
| For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of less than 1 000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species | $118,700 | $122,024 | ||
| For food-producing animals, residue depletion studies to establish a withdrawal period for an additional dosage form, dosage or route of administration | $11,855 | $12,187 | ||
| For food-producing animals (once an acceptable daily intake with a safety factor of 1 000 or less has been established), metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in an additional species | $59,332 | $60,994 | ||
| Chemistry and manufacturing data for a non-compendial medicinal ingredient of a drug |
$19,780 | $20,334 | ||
| Chemistry and manufacturing data to support one strength of a single dosage form | $19,780 | $20,334 | ||
| Chemistry and manufacturing data to support an additional strength of a single dosage form submitted at the same time as the item above | $9,893 | $10,171 | ||
| Documentation to support a change of manufacturer | $1,025 | $1,054 | ||
| Supplement to a new drug submission (SNDS) | Efficacy data to support an additional indication in one animal species | $51,445 | $52,886 | |
| Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one non-food animal species |
$39,557 | $40,665 | ||
| Efficacy and safety data (in the intended species) to support an indication in another animal species | $65,297 | $67,126 | ||
| Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration and dosage form and two indications in one animal species | $94,961 | $97,620 | ||
| Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species | $128,589 | $132,190 | ||
| Efficacy and safety data (in the intended species) to support the concurrent use of two drugs approved for the same animal species | $31,628 | $32,514 | ||
| Comparative (pharmacodynamic, clinical or bioavailability) data to support an additional route of administration | $11,855 | $12,187 | ||
| Comparative (pharmacodynamic, clinical or bioavailability) data to support each additional strength | $1,964 | $2,019 | ||
| For food-producing animals, residue depletion studies to establish a new withdrawal period for a change in the dosage or route of administration of an approved dosage form in one species | $11,855 | $12,187 | ||
| For food-producing animals, metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage and route of administration of an approved dosage form in an additional species | $59,332 | $60,994 | ||
| For food-producing animals, toxicity studies to support a change of an established acceptable daily intake, a maximum residue limit and a withdrawal period | $29,667 | $30,498 | ||
| For the concurrent use of two drugs in a species of food-producing animals, residue depletion studies to determine if an extension to existing withdrawal periods is required | $23,744 | $24,409 | ||
| Chemistry and manufacturing data to support a change in the source of a medicinal ingredient or its manufacturing process | $19,780 | $20,334 | ||
| Chemistry and manufacturing data to support a change in formulation or dosage form | $9,893 | $10,171 | ||
| Chemistry and manufacturing data to support a change in the packaging or sterilization process | $7,888 | $8,109 | ||
| Chemistry and manufacturing data to support an extension of the expiry date | $5,930 | $6,097 | ||
| Chemistry and manufacturing data to support the concurrent use of two drugs | $5,930 | $6,097 | ||
| Chemistry and manufacturing data to support a change in the manufacturing site for parenteral dosage form | $1,964 | $2,019 | ||
| Documentation to support a change to the brand name of a drug | $1,025 | $1,054 | ||
| Abbreviated new drug submission (ANDS) or supplement to an abbreviated new drug submission (SANDS) | Comparative (pharmacodynamic, clinical or bioavailability) data to support a single route of administration and dosage form | $11,855 | $12,187 | |
| For food-producing animals, residue depletion studies to confirm that the withdrawal periods for each species fall within the conditions of use for the Canadian reference product | $11,855 | $12,187 | ||
| Chemistry and manufacturing data for a non-compendial medicinal ingredient of a drug |
$19,780 | $20,334 | ||
| Chemistry and manufacturing data to support a single dosage form | $19,780 | $20,334 | ||
| Documentation to support
(a) a change of manufacturer, in the case of an abbreviated new drug submission; or (b) a change to the brand name of a drug, in the case of a supplement to an abbreviated new drug submission |
$1,025 | $1,054 | ||
| Preclinical submission | Efficacy and safety data (in the intended species) and protocol to support the conduct of clinical studies relative to a single dosage form, route of administration and indication in one species | $19,780 | $20,334 | |
| Efficacy data and protocol to support the conduct of clinical studies relative to a single route of administration and indication with a dosage form for which a notice of compliance has been issued for use in the species to be treated | $15,816 | $16,259 | ||
| For food-producing animals, toxicity, metabolism and residue depletion studies to establish a temporary acceptable daily intake, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species | $59,332 | $60,994 | ||
| For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1 000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species | $89,035 | $91,528 | ||
| For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of less than 1 000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species | $118,700 | $122,024 | ||
| For food-producing animals (once an acceptable daily intake with a safety factor of 1 000 or less has been established), metabolism studies to establish a withdrawal period for a single dosage form, dosage and route of administration in an additional species | $29,667 | $30,498 | ||
| Chemistry and manufacturing data to support a single dosage form containing a non-compendial medicinal ingredient | $19,780 | $20,334 | ||
| Chemistry and manufacturing data to support a single dosage form containing a compendial medicinal ingredient | $9,893 | $10,171 | ||
| Sale of new drug for emergency treatment | Information and material to support the sale of a new drug to be used in the emergency treatment of a non-food-producing animal | $64 | $66 | |
| Information and material to support the sale of a new drug to be used in the emergency treatment of a food-producing animal | $127 | $131 | ||
| Experimental studies certificate | Information and material to support the issuance of an experimental studies certificate for a drug to be administered to a non-food-producing animal | $1,181 | $1,215 | |
| Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that of a previously authorized experimental studies certificate for a drug to be administered to a non-food-producing animal | $592 | $609 | ||
| Information and material to support the issuance of an experimental studies certificate for a drug to be administered to a food-producing animal | $3,558 | $3,658 | ||
| Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that of a previously authorized experimental studies certificate for a drug to be administered to a food-producing animal | $592 | $609 | ||
| Notifiable change or protocol review | Information and material to support an application for a notifiable change | $5,316 | $5,465 | |
| A protocol that is filed with the Minister and may support a new drug submission, an abbreviated new drug submission, a supplement to a new drug submission or abbreviated new drug submission, a preclinical submission or information and material that is filed for the purpose of obtaining an experimental studies certificate | $5,316 | $5,465 |
| Section in the Fees in Respect of Drugs and Medical Devices Order | Activity | Fee as of April 1, 2026 | Fee as of April 1, 2027 |
|---|---|---|---|
| Sections 33 and 41 | Fabrication — sterile dosage form | $50,401 | $51,813 |
| Sections 34 and 42 | Importation | $38,916 | $40,006 |
| Sections 35 and 43 | Fabrication — non-sterile dosage form | $37,365 | $38,412 |
| Sections 36 and 44 | Distribution | $19,864 | $20,421 |
| Sections 37 and 45 | Wholesaling | $11,592 | $11,917 |
| Sections 38 and 46 | Packaging/labelling | $7,286 | $7,491 |
| Sections 39 and 47 | Testing | $6,014 | $6,183 |
| Section 40 | Foreign site (each) | $1,107 | $1,138 |
| Section in the Fees in Respect of Drugs and Medical Devices Order | Activity | Fee as of April 1, 2026 | Fee as of April 1, 2027 |
|---|---|---|---|
| Sections 33 and 41 | Fabrication — sterile dosage form | $50,401 | $51,813 |
| Sections 34 and 42 | Importation | $38,916 | $40,006 |
| Sections 35 and 43 | Fabrication — non-sterile dosage form | $37,365 | $38,412 |
| Sections 36 and 44 | Distribution | $19,864 | $20,421 |
| Sections 37 and 45 | Wholesaling | $8,864 | $9,113 |
| Sections 38 and 46 | Packaging/labelling | $7,286 | $7,491 |
| Sections 39 and 47 | Testing | $6,014 | $6,183 |
| Section 40 | Foreign site (each) | $1,107 | $1,138 |
| Section in the Fees in Respect of Drugs and Medical Devices Order | Type of drug | Fee as of April 1, 2026 | Fee as of April 1, 2027 |
|---|---|---|---|
| Section 52 | Disinfectant | $1,760 | $1,810 |
| Non-prescription | $3,391 | $3,486 | |
| Drug other than one referred to in item 1 or 2 (above) | $5,626 | $5,784 |
| Section in the Fees in Respect of Drugs and Medical Devices Order | Type of drug | Fee as of April 1, 2026 | Fee as of April 1, 2027 |
|---|---|---|---|
| Section 56 | Veterinary drug | $577 | $594 |
Part 3 — Medical devices
| Section in the Fees in Respect of Drugs and Medical Devices Order | Category | Fee as of April 1, 2026 | Fee as of April 1, 2027 |
|---|---|---|---|
| Section 60 | Applications for Class II licence | $643 | $662 |
| Applications for Class II licence amendment | $331 | $341 | |
| Applications for Class III licence | $14,163 | $14,560 | |
| Applications for Class III licence (near patient) | $30,169 | $31,014 | |
| Applications for Class III licence amendment — changes in manufacturing | $4,470 | $4,596 | |
| Applications for Class III licence amendment — significant changes not related to manufacturing | $11,369 | $11,688 | |
| Applications for Class IV licence | $30,713 | $31,573 | |
| Applications for Class IV licence amendment — changes in manufacturing | $4,470 | $4,596 | |
| Applications for Class IV licence amendment — significant changes not related to manufacturing | $16,251 | $16,707 | |
| Applications for Class II, III or Class IV licence or licence amendment — private label medical device | $179 | $185 |
| Section in the Fees in Respect of Drugs and Medical Devices Order | Fee category | Fee as of April 1, 2026 | Fee as of April 1, 2027 |
|---|---|---|---|
| Section 71 | Medical device | $5,519 | $5,674 |
| Section in the Fees in Respect of Drugs and Medical Devices Order | Fee category | Fee as of April 1, 2026 | Fee as of April 1, 2027 |
|---|---|---|---|
| Section 77 | Medical device | $460 | $473 |
| Section in the Fees in Respect of Drugs and Medical Devices Order | Fee category | Fees as of May 31, 2026 | Fees as of April 1, 2027 |
|---|---|---|---|
| Section 27 | Biocide full review — novel biocide | $42,394 | $43,582 |
| Biocide full review — tier I | $8,742 | $8,987 | |
| Biocide full review — tier II | $11,664 | $11,991 | |
| Biocide full review — tier III | $13,753 | $14,139 | |
| Biocide comparison — labelling only | $2,795 | $2,874 | |
| Biocide comparison — administrative application | $992 | $1,020 | |
| Biocide — use of foreign decisions | $3,153 | $3,242 | |
| Biocide monograph | $1,893 | $1,947 | |
| Biocide major change — monograph | $1,387 | $1,426 | |
| Biocide major change — quality and risks | $5,040 | $5,182 | |
| Biocide minor change | $1,387 | $1,426 |
| Section in the Fees in Respect of Drugs and Medical Devices Order | Type of drug | Fee as of May 31, 2026 | Fee as of April 1, 2027 |
|---|---|---|---|
| Section 58 | Biocide | $1,562 | $1,606 |
DEPARTMENT OF HEALTH
PATENT ACT
Notice of annual increase of fee pursuant to the Certificate of Supplementary Protection Regulations
Notice is hereby given that, in keeping with subsection 9(1) of the Certificate of Supplementary Protection Regulations, the fee will increase by the annual 2% amount, rounded up to the nearest dollar.
The current fee and the fee updated as of April 1, 2027, are listed below.
Any inquiries or comments about the updated fee can be directed to Rosslynn Miller-Lee, Director General, Business Facilitation and Modernization Directorate, Health Products and Food Branch, 613‑327‑0798 (telephone) or cro-brc@hc-sc.gc.ca (email).
| Type of certificate | Subsection in Certificate of Supplementary Protection Regulations | Fee as of April 1, 2026 | Fee as of April 1, 2027 |
|---|---|---|---|
| Certificate of Supplementary Protection | 9(1) | $10,776 | $10,992 |
PRIVY COUNCIL OFFICE
Appointment opportunities
The Government of Canada is committed to appointing highly qualified individuals to Governor in Council positions through competency-based assessments. Governor in Council appointments are guided by principles of competency, transparency and respect for diversity. These principles ensure appointees are held to the high standards of professionalism, responsibility, and ethical behaviour. High quality and timely appointments ensure that the Government carries out its mandate and achieves its objectives in an efficient manner.
The Government of Canada is currently seeking applications from Canadians across the country who are interested in the following positions.
Current opportunities
The following opportunities for appointments to Governor in Council positions are currently open for applications. Every opportunity is open for a minimum of two weeks from the date of posting on the Governor in Council appointments website.
| Position | Organization | Closing date |
|---|---|---|
| President and Chief Executive Officer | Atomic Energy of Canada Limited | November 19, 2026 |
| Director | Canadian Tourism Commission | December 7, 2026 |
| Member | Immigration and Refugee Board | November 26, 2026 |
| Governor | International Development Research Centre | December 10, 2026 |
| Member — All Divisions | Parole Board of Canada | November 24, 2026 |
| Vice-Chairperson | Social Security Tribunal of Canada | November 26, 2026 |